BDRX
$0.70+0.02 (+2.25%)
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers...
Recent News
European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading; Drop Over 2% for Week
European equities traded in the US as American depositary receipts were sharply lower late Friday mo
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading
European equities traded in the US as American depositary receipts were down sharply late Thursday m
European Equities Traded in the US as American Depositary Receipts Higher Monday
European equities traded in the US as American depositary receipts were rising on Monday morning, up
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
European equities traded in the US as American depositary receipts were lower late Friday morning, d
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading
European equities traded in the US as American depositary receipts edged lower late Wednesday mornin